Abstract:Background: The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17, is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been described in several tumor types. Herein, we investigated the gene status of EGFR, HER2, and TOP2A in Chinese gastric carcinoma patients. We determined the rate of polysomy for chromosomes 7 and 17, and we attempted to clarify the relationship between EGFR, HER2, and TOP2A gene copy number and increased expression of their encoded proteins. Furthermore, we tried to address the relationship between alterations in EGFR, HER2, and TOP2A and chromosome polysomy.Methods: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods.Results: Forty-two percent of the cases showed EGFR overexpression; 16% showed EGFR FISH positive; 6% showed HER2 overexpression; and 11% showed HER2 gene amplification, including all six HER2 overexpression cases. TOP2A nuclear staining (nuclear index, NI) was determined in all 100 tumors: NI values ranged from 0.5 - 90%. Three percent of the tumors showed TOP2A gene amplification, which were all accompanied by HER2 gene amplification. Nineteen percent of the tumors showed chromosome 7 polysomy, and 16% showed chromosome 17 polysomy. Chromosome 7 polysomy correlated significantly with EGFR FISH-positivity, but was not associated with EGFR overexpression. HER2 overexpression associated significantly with HER2 gene amplification. TOP2A gene amplification was significantly associated with HER2 gene amplification. No relationship was found between alterations in the EGFR, HER2, and TOP2A genes and clinicopathologic variables of gastric carcinoma.Conclusion: The data from our study suggest that chromosome 7 polysomy may be responsible for increased EGFR gene copy number in gastric carcinomas, and that HER2 gene amplification may be the major reason for HER2 protein overexpression. A combined investigation of the gene status of EGFR, HER2, and TOP2A should facilitate the identification of a target therapeutic regimen for gastric carcinoma patients.

[Effects of Polysomy 17 on HER-2 Gene and Protein Expression and Its Clinicopathologic Significance in Breast Cancer].

Assessment and Significance of Human Epidermal Growth Factor Receptor 2 Gene Status in Breast Cancer with Polysomy of Chromosome 17

Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.

Genetic Alterations and Protein Expression of HER2 and Chromosome 17 Polysomy in Breast Cancer

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

Correlation Between Her-2/neu Protein Expression and Gene Status in Invasive Breast Cancer

Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization

Analysis of EGFR, HER2, and TOP2A Gene Status and Chromosomal Polysomy in Gastric Adenocarcinoma from Chinese Patients

The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population.

HER2 Amplification in Breast Cancer and Its Clinicopathological Implications

Reliability and Discriminant Validity of HER2 Gene Quantification and Chromosome 17 Aneusomy Analysis by Real-Time PCR in Primary Breast Cancer

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

Human Epidermal Growth Factor Receptor 2 Protein Expression Between Primary Breast Cancer and Paired Asynchronous Local-Regional Recurrences.

Clinicopathologic Significance of HER-2/neu Protein Expression and Gene Amplification in Gastric Carcinoma

HER2 Pro1170Ala Polymorphism is Associated with Decreased Survival Rate in HER2-negative Breast Cancer.

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression

The Effect of an Alternative Chromosome 17 Probe on Fluorescence in Situ Hybridization for the Assessment of HER2 Amplification in Invasive Breast Cancer

Loss of P53 Gene and Amplification of HER-2 Oncogene and Their Clinical Significance in Epithelial Ovarian Carcinomas

[Evaluation and Indication of Human Epithelial Growth Factor Receptor 2 Status in Breast Carcinoma with Amplified Chromosome].

Clinical Significance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer Patients